Early Detection
In Your Voice
AI-powered non-invasive lung cancer screening using only a smartphone. Transforming diagnostics with 97% clinical accuracy.
Proprietary Technology
Our advanced deep learning algorithms analyze thousands of micro-acoustic features in the human voice to detect physiological changes caused by lung cancer.
Voice Biomarkers
Lung cancer affects airflow and vocal cord function, creating unique acoustic signatures detectable by AI even in early stages before symptoms appear.
Deep Learning
Our proprietary ECO (Error-Corrective Optimization) technology processes MFCC features to identify patterns invisible to the human ear.
Zero Hardware
A purely software-based solution (SaMD) that runs on any standard smartphone, enabling massive scalability and accessibility.
Clinical Validation
Our technology has been rigorously tested and validated, delivering breakthrough results published in top-tier scientific journals.
97% AUC Accuracy
Achieved in a clinical study with 128 participants.
Tumor Size Correlation
Pilot study (N=20) showed strong correlation (r=0.75) with tumor size.
Published Research
Results published in Elsevier (2024), validating the scientific approach.
VocalDx China
We are pioneering the future of non-invasive diagnostics. With exclusive rights to the Chinese market and strategic partnerships with leading hospitals, VocalDx is poised to save millions of lives through early detection.
Class III
Medical Device Pathway
Exclusive
Scalable
Software-Only Solution